Measles virus (MV) is responsible for an acute respiratory tract infection and immunodepression and is among the primary causes of infant mortality in developing countries (3) . On rare occasions, MV infection can lead to severe acute and chronic neurological disorders known as subacute sclerosing panencephalitis and measles inclusion body encephalitis. The mechanisms of MV pathogenesis are not well elucidated, and a better understanding of MV entry into host cells is crucial.
The first step in viral infection is attachment of the virus to a cell surface receptor. The importance of this step has been shown with the identification of cell receptors for a number of human pathogenic viruses, including poliovirus, rhinovirus, Epstein-Barr virus, and human immunodeficiency virus (HIV) (7, 9, 11, 14, 19, 22, 26) . Entry of MV, like that of other enveloped viruses, occurs by binding to cell surface receptors followed by fusion of viral and cell membranes either at the plasma membrane, for viruses such as MV and HIV, or after internalization into acidic endosomes, for other enveloped viruses such as influenza virus. MV, a member of the Morbillivirus genus in the Paramyxoviridae family, is a negative-strand enveloped single-stranded RNA virus containing two membrane glycoproteins, the hemagglutinin (H) glycoprotein and the fusion (F) glycoprotein. During MV infection of human cells, the two MV envelope glycoproteins are expressed at the surface of the infected cells and induce cell-cell fusion leading to syncytium formation, characteristic of measles cytopathic effect. It has been shown for various paramyxoviruses that both the H and F proteins are necessary to produce syncytia. In permissiveness of a cell line to MV infection is also necessary to obtain MV-like cytopathic effect (28) .
MV exhibits a very limited host range; humans are the only known reservoir, although the virus can infect some monkey species. We thus speculated that the receptor could be important in determining the limited tropism of MV and could also be important in MV H/F-induced cell-cell fusion. We previously isolated a monoclonal antibody (MAb), called MCI20.6, for its ability to block VV-H/F-induced syncytium formation. MCI20.6 blocked MV binding and infection and recognized a 57-to 67-kDa membrane glycoprotein present in human and simian cells but not in cell lines of species nonpermissive to MV (20) .
In this work, N-terminal amino acid sequencing identified gp57/67 as human membrane cofactor protein (CD46). CD46 is a member of the regulators of complement activation gene cluster and is involved in protecting cells from autologous complement-mediated damage (16, 17 (10) . The cells were washed prior to incubation with an FITCconjugated goat anti-mouse immunoglobulin. All of the flow cytometric analyses were carried out on a FACStar (Becton Dickinson). The hemagglutinin units were determined by hemagglutination of vervet monkey erythrocytes as described previously (20) .
Fusion assay and virus infectivity determination. For the fusion assay, the vaccinia virus recombinant VV-H/F was used (27) . Human cells were infected with VV-H/F at 0.1 PFU per cell, and murine cells were infected at 1 PFU per cell. The cytopathic effect was observed 18 h postinfection (p.i.) and photographed on an Olympus inverted microscope.
For virus infectivity determination, cells were infected with MV at 1 PFU per cell for 6 h at 37°C, washed three times, and put into culture. Two to three days p.i., cells were centrifuged and the supernatant was assayed for plaque formation on Vero cells. For this assay, 5 x 105 Vero cells were plated in six-well dishes and incubated with 10-fold a.
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NH2 -cys-glu-glu-pro2-tr=--he-glu-ala-t-glu-leu-ile-gly-lys FIG. 1 . The N-terminal amino acid sequence of gp57/67 immunopurified with MAb MCI20.6 corresponds to the N-terminal sequence (minus the signal sequence) of human membrane cofactor protein (CD46 [17] ). The 15 N-terminal amino acids of gp57/67 (a; the X indicates nondetermined amino acids) are aligned with the N-terminal amino acids of the CD46 molecule (b; underlined amino acids correspond to the unknown residues in the gp57/67 sequence).
dilutions of infected-cell supematants. Three to four days later, cells were fixed in 10% formalin and stained in a methylene blue solution, and plaques were counted. Background was determined from supernatants taken 1 h after cell washes.
Cell labeling and immunoprecipitation. For surface iodination of cells, the glucose-lactoperoxidase technique was used as described previously (12) . For metabolic labeling, cells were incubated in labeling medium (methionine-and cysteine-free medium containing dialyzed fetal calf serum) for tical electrophoretic profiles, providing further evidence that MCI20.6 recognized the CD46 antigen ( Fig. 2A) . Expression of CD46 is complex, and because of alternate splicing events and variation in N and 0 glycosylation, the CD46 gene gives rise to proteins of heterogeneous Mr (25) . Stable expression of CD46 in murine cells enables them to bind MV. We previously showed that murine cells were not able to bind MV. Thus, to determine whether the CD46 molecule could confer MV-binding capacity to cells nonpermissive for MV infection, murine fibroblast (Ltk-) and B-cell (M12) lines were transfected with CD46 cDNA under the control of the 0-actin promoter; stable cell lines expressing CD46 were obtained, as shown by immunoprecipitation of the CD46 molecule with MAb MCI20.6 from 25I-surfacelabeled transfected cells and by flow cytometry (Fig. 2B and  3 ). These transfected cell lines, L.CD46 and M12.CD46, were incubated with various amounts of MV and assayed for MV binding. MV bound to human Jurkat (99%), L.CD46 (84%), and M12.CD46 (63%) cells (Fig. 4, lower graphs) VV-H/F (28) . To determine whether CD46, besides allowing MV binding to murine cells, could also confer cell-cell fusion and thus possibly virus-cell fusion, L.CD46 and M12.CD46 cells were infected with VV-H/F and examined for syncytia. (Fig. Sb) and HeLaT4 (Fig. 5d) cells and the CD46-transfected murine cells (Fig. 5h and j) produced syncytia, whereas the untransfected L and M12 cells did not ( Fig. 5f and j) L.CD46 and M12.CD46 cells for viral production. Cells were infected with MV at 1 PFU per cell, and 48 or 72 h p.i., the supernatants of these MV-infected cells were assayed for the presence of infectious viral particles. MV replication was detected in the supernatants of Jurkat and M12.CD46 cells ( Table 1 ). The PFU due to virus carried over from the initial infection (approximately 40 PFUI/ml) was determined from supernatant taken 1 h after infected cells had been washed. Little infectious virus could be recovered from infected M12 cell supernatants, and in four separate experiments, at least 100-fold more virus was recovered from M12.CD46 cell supernatants. No virus could be detected in MV-infected L cells or in L.CD46 supernatants. These assays were done at 48 h p.i. for Jurkat cells (i.e., prior to extensive cell mortality) and at 72 h p.i. for murine cells. At 48 h p.i., only low levels of virus were detected in infected M12.CD46 supernatants compared with levels found at 72 h p.i. To determine whether infectious virus recovered from infected M12 cell supernatants was carried over from the initial infection, MV-infected cells were metabolically labeled and lysed, and immunoprecipitation was carried out to detect cell biosynthesis of viral H glycoprotein. Figure 6 shows that cellsynthesized labeled MV H is present in Jurkat and M12.CD46 cells but not in M12 cells (lanes 2, 4, and 6). Newly synthesized MV H could not be detected in L or L.CD46 cells (data not shown). Thus, in agreement with MV-induced fusion results, viral replication was observed in M12.CD46 cells and not in L.CD46 or parental murine cells. 
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DISCUSSION
A MAb (MCI20.6) which inhibits MV binding, syncytium formation, and infection was previously isolated in our laboratory (20 CD46 is a member of the regulators of complement activation gene cluster located on chromosome 1 at q3.2 (17) . The members of this gene cluster are structurally related, as they all possess 60-amino-acid repeating motifs called short consensus repeats, and they all bind C3b and C4b (reviewed in reference 15). CD46 has cofactor activity, meaning that it binds to membrane-bound C3b and C4b and allows C3b and 4b to be degraded by factor I, a plasma serine protease (15) . CD46 thus provides a control mechanism which protects cells from autologous complement-mediated self-damage (16) .
CD46 is expressed on most human cell types with the exception of erythrocytes. The CD46 homolog is, however, expressed on certain primate erythrocytes (23) . This finding is in accordance with the MV binding profile. MV binds to most human tissues except erythrocytes and can agglutinate erythrocytes of certain primate species. Furthermore, MAb MCI20.6 was found to cross-react with a simian gp67, likely a simian CD46 homolog present in Vero simian cells (20) . The murine homolog of CD46 has not yet been characterized.
Expression of CD46 in murine cells allowed MV to bind to the cells but in a less efficient manner than to human cells. It has been shown that alternate splicing of CD46 mRNA can give rise to 14 isoforms of CD46 (25) . Since the CD46-expressing murine cells were transfected with one cDNA, the weaker binding to CD46-expressing murine cells could reflect the importance of certain CD46 isoforms in MVbinding efficiency. This hypothesis is currently under investigation.
The expression of human CD46 in mouse cells was also sufficient to render them sensitive to MV glycoproteininduced fusion. In the case of HIV, expression of the HIV receptor, human CD4, in mouse cells confers HIV-binding capacity but does not allow HIV glycoprotein-induced cell fusion (18) . This finding suggests that the murine cells used may lack a factor necessary for HIV glycoprotein-induced cell fusion but possess one necessary for MV glycoproteininduced cell fusion. HIV has been shown to enter CD4-cells by a complement component C3-dependent pathway (4, 13) .
This can be excluded in the case of MV since all of our experiments were done in the presence of heat-inactivated heterologous serum (fetal calf serum). Heating destroys C3-binding activity, and it was shown for HIV that the C3-mediated pathway of entry requires autologous nonheated serum (13) .
Our results show that depending on the murine cell line used, expression of CD46 in murine cells is not always sufficient to allow MV replication and production of infectious virus. Indeed, M12.CD46 (a B-cell lymphoma) pro (2) . Whether the difference in replication ability between M12.CD46 and L.CD46 cells is related to cell type, rate of cell proliferation, or simply the nature of the cell lines is currently being studied.
Work on viral receptors has revealed a number of viruses that use receptors of the immune system: CD4 for HIV (7, 14) , CR2 for Epstein-Barr virus (9, 22) , and ICAM-1 for major group rhinoviruses (11, 26) . MV also uses a receptor involved in the immune system and more specifically in the complement pathway. Certain 
